
Maarten C C M Hulshof

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/114982/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. New England Journal of Medicine, 2012, 366, 2074-2084.	13.9	4,296
2	Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncology, The, 2015, 16, 1090-1098.	5.1	1,861
3	Patterns of Recurrence After Surgery Alone Versus Preoperative Chemoradiotherapy and Surgery in the CROSS Trials. Journal of Clinical Oncology, 2014, 32, 385-391.	0.8	389
4	Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. Journal of Clinical Oncology, 2021, 39, 1995-2004.	0.8	291
5	Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncology, The, 2018, 19, 965-974.	5.1	211
6	Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study). Journal of Clinical Oncology, 2021, 39, 2816-2824.	0.8	151
7	Lymph Node Retrieval During Esophagectomy With and Without Neoadjuvant Chemoradiotherapy. Annals of Surgery, 2014, 260, 786-793.	2.1	134
8	Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2237-2242.	3.3	128
9	CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer, 2018, 18.877.	1.1	115
10	Improving locoregional hyperthermia delivery using the 3-D controlled AMC-8 phased array hyperthermia system: A preclinical study. International Journal of Hyperthermia, 2009, 25, 581-592.	1.1	98
11	Influence of bladder and rectal volume on spatial variability of a bladder tumor during radical radiotherapy. International Journal of Radiation Oncology Biology Physics, 2003, 55, 835-841.	0.4	92
12	Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial. Journal of Clinical Oncology, 2018, 36, 268-275.	0.8	91
13	Tumor motion and deformation during external radiotherapy of bladder cancer. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1551-1558.	0.4	76
14	Definitive chemoradiation for patients with inoperable and/or unresectable esophageal cancer: locoregional recurrence pattern. Ecological Management and Restoration, 2015, 28, 453-459.	0.2	73
15	microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients. Gastroenterology, 2018, 155, 784-798.	0.6	70
16	Hypofractionation in glioblastoma multiforme. Radiotherapy and Oncology, 2000, 54, 143-148.	0.3	67
17	Effects of age and comorbidity on treatment and survival of patients with muscleâ€invasive bladder cancer. International Journal of Cancer, 2014, 135, 905-912.	2.3	65
18	Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study. Annals of Oncology, 2017, 28, 519-527.	0.6	65

#	Article	IF	CITATIONS
19	Concomitant boost radiotherapy for muscle invasive bladder cancer. Radiotherapy and Oncology, 2003, 68, 75-80.	0.3	63
20	Distribution of lymph node metastases in esophageal carcinoma [TIGER study]: study protocol of a multinational observational study. BMC Cancer, 2019, 19, 662.	1.1	62
21	Intravesical markers for delineation of target volume during external focal irradiation of bladder carcinomas. Radiotherapy and Oncology, 2007, 84, 49-51.	0.3	59
22	Pre-treatment CT radiomics to predict 3-year overall survival following chemoradiotherapy of esophageal cancer. Acta Oncológica, 2018, 57, 1475-1481.	0.8	58
23	Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative. Acta Oncológica, 2018, 57, 195-202.	0.8	55
24	Hyperbaric Oxygen Therapy for Cognitive Disorders after Irradiation of the Brain. Strahlentherapie Und Onkologie, 2002, 178, 192-198.	1.0	54
25	Prognostic Factors in Glioblastoma Multiforme 10 Years Experience of a Single Institution. Strahlentherapie Und Onkologie, 2001, 177, 283-290.	1.0	52
26	Effects of hyperthermia on the central nervous system: What was learnt from animal studies?. International Journal of Hyperthermia, 2005, 21, 473-487.	1.1	51
27	Behavior of Lipiodol Markers During Image Guided Radiotherapy of Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 309-314.	0.4	51
28	Effects of hyperthermia on the peripheral nervous system: a review. International Journal of Hyperthermia, 2004, 20, 371-391.	1.1	50
29	Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial. Annals of Oncology, 2018, 29, 445-451.	0.6	50
30	Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET. International Journal of Hyperthermia, 2006, 22, 149-160.	1.1	47
31	Feasibility and repeatability of PET with the hypoxia tracer [18F]HX4 in oesophageal and pancreatic cancer. Radiotherapy and Oncology, 2015, 116, 94-99.	0.3	44
32	Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2–Positive Esophageal Adenocarcinoma: TRAP Study. Journal of Clinical Oncology, 2020, 38, 462-471.	0.8	44
33	Brachytherapy. Cancer, 2000, 88, 2796-2802.	2.0	43
34	Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma. Ecological Management and Restoration, 2014, 27, 380-387.	0.2	41
35	Minimal displacement of novel self-anchoring catheters suitable for temporary prostate implants. Radiotherapy and Oncology, 2006, 80, 69-72.	0.3	40
36	Preoperative chemoradiotherapy in locally advanced gastric cancer, a phase I/II feasibility and efficacy study. Radiotherapy and Oncology, 2014, 112, 284-288.	0.3	40

#	Article	IF	CITATIONS
37	Evaluation of delivered dose for a clinical daily adaptive plan selection strategy for bladder cancer radiotherapy. Radiotherapy and Oncology, 2015, 116, 51-56.	0.3	39
38	Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. Annals of Surgical Oncology, 2017, 24, 2282-2290.	0.7	39
39	Survival after treatment for carcinoma invading bladder muscle: a Dutch population-based study on the impact of hospital volume. BJU International, 2012, 110, 226-232.	1.3	38
40	Quantification of respiration-induced esophageal tumor motion using fiducial markers and four-dimensional computed tomography. Radiotherapy and Oncology, 2016, 118, 492-497.	0.3	38
41	Marker-based quantification of interfractional tumor position variation and the use of markers for setup verification in radiation therapy for esophageal cancer. Radiotherapy and Oncology, 2015, 117, 412-418.	0.3	37
42	Prospective treatment planning to improve locoregional hyperthermia for oesophageal cancer. International Journal of Hyperthermia, 2006, 22, 375-389.	1.1	36
43	Finite element based bladder modeling for imageâ€guided radiotherapy of bladder cancer. Medical Physics, 2011, 38, 142-150.	1.6	34
44	Impact of Surgical Approach on Long-term Survival in Esophageal Adenocarcinoma Patients With or Without Neoadjuvant Chemoradiotherapy. Annals of Surgery, 2018, 267, 892-897.	2.1	34
45	Influence of body composition and muscle strength on outcomes after multimodal oesophageal cancer treatment. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 756-767.	2.9	34
46	Accuracy and reproducibility of 3D-CT measurements for early response assessment of chemoradiotherapy in patients with oesophageal cancer. European Journal of Surgical Oncology, 2011, 37, 1064-1071.	0.5	33
47	Health-related quality of life in curatively-treated patients with esophageal or gastric cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2020, 154, 103069.	2.0	32
48	Combination of biodegradable stent placement and single-dose brachytherapy is associated with an unacceptably high complication rate in the treatment of dysphagia from esophageal cancer. Gastrointestinal Endoscopy, 2012, 76, 267-274.	0.5	31
49	Re-Irradiation of the Human Spinal Cord. Strahlentherapie Und Onkologie, 2002, 178, 453-456.	1.0	30
50	Clinical Results of a Concomitant Boost Radiotherapy Technique for Muscle-Invasive Bladder Cancer. Strahlentherapie Und Onkologie, 2008, 184, 313-318.	1.0	30
51	The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis. Cancers, 2019, 11, 80.	1.7	30
52	Effectiveness and toxicity of single-fraction radiotherapy with 1×8Gy for metastatic spinal cord compression. Radiotherapy and Oncology, 2005, 75, 70-73.	0.3	29
53	Burden of spousal caregivers of stage II and III esophageal cancer survivors 3Âyears after treatment with curative intent. Supportive Care in Cancer, 2015, 23, 3589-3598.	1.0	29
54	Clinical results of conformal versus intensity-modulated radiotherapy using a focal simultaneous boost for muscle-invasive bladder cancer in elderly or medically unfit patients. Radiation Oncology, 2016, 11, 45.	1.2	29

#	Article	IF	CITATIONS
55	A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas. Scientific Reports, 2018, 8, 13281.	1.6	28
56	Platinum exposure and causeâ€specific mortality among patients with testicular cancer. Cancer, 2020, 126, 628-639.	2.0	28
57	Prediction of survival in patients with oesophageal or junctional cancer receiving neoadjuvant chemoradiotherapy and surgery. British Journal of Surgery, 2016, 103, 1039-1047.	0.1	27
58	Preoperative chemoradiation combined with regional hyperthermia for patients with resectable esophageal cancer. International Journal of Hyperthermia, 2009, 25, 79-85.	1.1	26
59	Variations in treatment policies and outcome for bladder cancer in the Netherlands. European Journal of Surgical Oncology, 2010, 36, S100-S107.	0.5	26
60	Conditional survival after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer. British Journal of Surgery, 2020, 107, 1053-1061.	0.1	26
61	Thermal dosimetry for bladder hyperthermia treatment. An overview. International Journal of Hyperthermia, 2016, 32, 417-433.	1.1	25
62	Hospital of Diagnosis Influences the Probability of Receiving Curative Treatment for Esophageal Cancer. Annals of Surgery, 2018, 267, 303-310.	2.1	25
63	A Prospective longitudinal study comparing the impact of external radiation therapy with radical prostatectomy on health related quality of life (HRQOL) in prostate cancer patients. Prostate, 2004, 58, 354-365.	1.2	24
64	Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. BMC Cancer, 2014, 14, 56.	1.1	24
65	18F-FDG PET-CT after Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients to Optimize Surgical Decision Making. PLoS ONE, 2015, 10, e0133690.	1.1	24
66	Effects of hyperbaric oxygen and normobaric carbogen on the radiation response of the rat rhabdomyosarcoma R1H 1 1This work was partially financed by the German Cancer Aid and the Fonds Ophthalmopathy, AMC Amsterdam, The Netherlands International Journal of Radiation Oncology Biology Physics, 2001, 51, 1037-1044.	0.4	23
67	A feasibility study in oesophageal carcinoma using deep loco-regional hyperthermia combined with concurrent chemotherapy followed by surgery. International Journal of Hyperthermia, 2004, 20, 647-659.	1.1	23
68	Chemoradiation induces epithelialâ€ŧoâ€mesenchymal transition in esophageal adenocarcinoma. International Journal of Cancer, 2019, 145, 2792-2803.	2.3	23
69	Impact of pathological tumor response after CROSS neoadjuvant chemoradiotherapy followed by surgery on long-term outcome of esophageal cancer: a population-based study. Acta Oncológica, 2021, 60, 497-504.	0.8	23
70	Control over structure-specific flexibility improves anatomical accuracy for point-based deformable registration in bladder cancer radiotherapy. Medical Physics, 2013, 40, 021702.	1.6	22
71	Lack of perfusion enhancement after administration of nicotinamide and carbogen in patients with glioblastoma: a 99mTc-HMPAO SPECT study. Radiotherapy and Oncology, 1998, 48, 135-142.	0.3	21
72	Influence of the Extent and Dose of Radiation on Complications After Neoadjuvant Chemoradiation and Subsequent Esophagectomy With Gastric Tube Reconstruction With a Cervical Anastomosis. International Journal of Radiation Oncology Biology Physics, 2017, 97, 813-821.	0.4	21

#	Article	IF	CITATIONS
73	Health-related quality of life and psychosocial factors in patients with prostate cancer scheduled for radical prostatectomy or external radiation therapy. BJU International, 2003, 92, 217-222.	1.3	20
74	A feasibility study of interstitial hyperthermia plus external beam radiotherapy in glioblastoma multiforme using the multi electrode current source (MECS) system. International Journal of Hyperthermia, 2004, 20, 451-463.	1.1	20
75	Differential responses of cellular immunity in patients undergoing neoadjuvant therapy followed by surgery for carcinoma of the oesophagus. Cancer Immunology, Immunotherapy, 2008, 57, 1837-1847.	2.0	19
76	Treatment strategies in recurrent esophageal or junctional cancer. Ecological Management and Restoration, 2017, 30, 1-9.	0.2	18
77	Reduced inter-observer and intra-observer delineation variation in esophageal cancer radiotherapy by use of fiducial markers. Acta Oncológica, 2019, 58, 943-950.	0.8	18
78	Postoperative Complications and Long-Term Quality of Life After Multimodality Treatment for Esophageal Cancer: An Analysis of the Prospective Observational Cohort Study of Esophageal-Gastric Cancer Patients (POCOP). Annals of Surgical Oncology, 2021, 28, 7259-7276.	0.7	18
79	Long-term health-related quality of life after McKeown and Ivor Lewis esophagectomy for esophageal carcinoma. Ecological Management and Restoration, 2020, 33, .	0.2	18
80	Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes. Annals of Surgical Oncology, 2015, 22, 766-771.	0.7	17
81	Improving hyperthermia treatment planning for the pelvis by accurate fluid modeling. Medical Physics, 2016, 43, 5442-5452.	1.6	17
82	Interfractional variability of respiration-induced esophageal tumor motion quantified using fiducial markers and four-dimensional cone-beam computed tomography. Radiotherapy and Oncology, 2017, 124, 147-154.	0.3	17
83	Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis. Cancers, 2019, 11, 530.	1.7	17
84	The dynamics of HER2 status in esophageal adenocarcinoma. Oncotarget, 2018, 9, 26787-26799.	0.8	17
85	Management of benign lymphoepithelial lesions of the parotid gland in human immunodeficiency virus-positive patients. European Archives of Oto-Rhino-Laryngology, 1998, 255, 427-429.	0.8	16
86	A voxel-based finite element model for the prediction of bladder deformation. Medical Physics, 2011, 39, 55-65.	1.6	16
87	Reduction of heart volume during neoadjuvant chemoradiation in patients with resectable esophageal cancer. Radiotherapy and Oncology, 2015, 114, 91-95.	0.3	16
88	Bladder-Sparing Chemoradiotherapy Combined with Immune Checkpoint Inhibition for Locally Advanced Urothelial Bladder Cancer—A Review. Cancers, 2022, 14, 38.	1.7	16
89	Supraclavicular node disease is not an independent prognostic factor for survival of esophageal cancer patients treated with definitive chemoradiation. Acta OncolÃ ³ gica, 2017, 56, 33-38.	0.8	15
90	Short-Course External Beam Radiotherapy Versus Brachytherapy for Palliation of Dysphagia in Esophageal Cancer: A Matched Comparison of Two Prospective Trials. Journal of Thoracic Oncology, 2020, 15, 1361-1368.	0.5	15

#	Article	IF	CITATIONS
91	BioXmark® liquid fiducial markers for image-guided radiotherapy in muscle invasive bladder cancer: a safety and performance trial. British Journal of Radiology, 2020, 93, 20200241.	1.0	15
92	Reduction in cardiac volume during chemoradiotherapy for patients with esophageal cancer. Radiotherapy and Oncology, 2013, 109, 200-203.	0.3	14
93	Effectiveness of Neoadjuvant Chemoradiotherapy for Early-Stage Esophageal Cancer. Journal of Clinical Oncology, 2015, 33, 288-289.	0.8	14
94	NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial). BMC Medical Physics, 2008, 8, 3.	2.4	13
95	Radiotherapy combined with hyperthermia for primary malignant melanomas of the esophagus. Ecological Management and Restoration, 2010, 23, E42-E47.	0.2	13
96	Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 36-37, 45-52.	1.0	13
97	Independent position correction on tumor and lymph nodes; consequences for bladder cancer irradiation with two combined IMRT plans. Radiation Oncology, 2010, 5, 53.	1.2	12
98	Comparison of two different 70 MHz applicators for large extremity lesions: Simulation and application. International Journal of Hyperthermia, 2010, 26, 376-388.	1.1	12
99	Chemoradiotherapy in tumours of the oesophagus and gastro-oesophageal junction. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 551-563.	1.0	12
100	The role of definitive chemoradiation in patients with non-metastatic oesophageal cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 36-37, 53-59.	1.0	12
101	Feasibility of cone beam CT-guided library of plans strategy in pre-operative gastric cancer radiotherapy. Radiotherapy and Oncology, 2020, 149, 49-54.	0.3	12
102	Relation between body size and temperatures during locoregional hyperthermia of oesophageal cancer patients. International Journal of Hyperthermia, 2008, 24, 663-674.	1.1	11
103	Improving bladder cancer treatment with radiotherapy using separate intensity modulated radiotherapy plans for boost and elective fields. Journal of Medical Imaging and Radiation Oncology, 2010, 54, 256-263.	0.9	11
104	Clinical validation of a novel thermophysical bladder model designed to improve the accuracy of hyperthermia treatment planning in the pelvic region. International Journal of Hyperthermia, 2018, 35, 383-397.	1.1	11
105	Tumorâ€immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas. Journal of Pathology, 2022, 256, 282-296.	2.1	11
106	The effect of on-line position correction on the dose distribution in focal radiotherapy for bladder cancer. Radiation Oncology, 2009, 4, 38.	1.2	10
107	Visibility of fiducial markers used for imageâ€guided radiation therapy on optical coherence tomography for registration with <scp>CT</scp> : An esophageal phantom study. Medical Physics, 2017, 44, 6570-6582.	1.6	10
108	Comparison of carina-based versus bony anatomy-based registration for setup verification in esophageal cancer radiotherapy. Radiation Oncology, 2018, 13, 48.	1.2	10

#	Article	IF	CITATIONS
109	COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2019, 9, 684.	1.3	10
110	A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer. Acta OncolÃ ³ gica, 2020, 59, 895-903.	0.8	10
111	Lessons learned from hyperthermia. International Journal of Radiation Oncology Biology Physics, 2003, 57, 596-597.	0.4	9
112	Neoadjuvant chemoradiotherapy followed by esophagectomy does not increase morbidity in patients over 70. Ecological Management and Restoration, 2013, 26, 510-516.	0.2	9
113	A Novel Liquid Fiducial Marker in Esophageal Cancer Image Guided Radiation Therapy: Technical Feasibility and Visibility on Imaging. Practical Radiation Oncology, 2019, 9, e506-e515.	1.1	9
114	Feasibility of extended chemoradiotherapy plus surgery for patients with cT4b esophageal carcinoma. European Journal of Surgical Oncology, 2020, 46, 626-631.	0.5	9
115	Reliability of temperature and SAR measurements at oesophageal tumour locations. International Journal of Hyperthermia, 2006, 22, 545-561.	1.1	8
116	Improved Clinical and Survival Outcomes After Esophagectomy for Cancer Over 25 Years. Annals of Thoracic Surgery, 2022, 114, 1118-1126.	0.7	8
117	A flexible 70 MHz phase-controlled double waveguide system for hyperthermia treatment of superficial tumours with deep infiltration. International Journal of Hyperthermia, 2017, 33, 1-14.	1.1	7
118	Gastro-oesophageal junction: to FLOT or to CROSS?. Acta OncolÃ ³ gica, 2020, 59, 233-236.	0.8	7
119	SOURCE: Prediction Models for Overall Survival in Patients With Metastatic and Potentially Curable Esophageal and Gastric Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 403-410.	2.3	7
120	Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer: A populationâ€based study. Cancer Science, 2022, , .	1.7	7
121	Quality of life after brachytherapy in patients with glioblastoma multiforme. European Journal of Cancer, 2004, 40, 1013-1020.	1.3	6
122	Gastric deformation models for adaptive radiotherapy: Personalized vs population-based strategy. Radiotherapy and Oncology, 2022, 166, 126-132.	0.3	6
123	What is the value of emission tomography studies in patients with a primary glioblastoma multiforme treated by 192Ir brachytherapy?. Acta Neurochirurgica, 2008, 150, 345-349.	0.9	5
124	Fusion of planning CT and cystoscopy images for bladder tumor delineation: A feasibility study. Medical Physics, 2013, 40, 051713.	1.6	5
125	Distribution of lymph node metastases on <scp>FDG</scp> â€ <scp>PET</scp> / <scp>CT</scp> in inoperable or unresectable oesophageal cancer patients and the impact on target volume definition in radiation therapy. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 520-527.	0.9	5
126	A biological modeling based comparison of two strategies for adaptive radiotherapy of urinary bladder cancer. Acta Oncológica, 2016, 55, 1009-1015.	0.8	5

#	Article	IF	CITATIONS
127	Dosimetric Benefits of Midposition Compared With Internal Target Volume Strategy for Esophageal Cancer Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 103, 491-502.	0.4	5
128	The Feasibility and Utility of Cystoscopy-Guided Hydrogel Marker Placement in Patients With Muscle-Invasive Bladder Cancer. Practical Radiation Oncology, 2020, 10, 195-201.	1.1	5
129	Long-Term Quality of Life Following Transthoracic and Transhiatal Esophagectomy for Esophageal Cancer. Journal of Gastrointestinal Surgery, 2021, 25, 1657-1666.	0.9	5
130	Reply to E.C. Smyth et al. Journal of Clinical Oncology, 2014, 32, 3081-3082.	0.8	4
131	Density override in treatment planning to mitigate the dosimetric effect induced by gastrointestinal gas in esophageal cancer radiation therapy. Acta Oncológica, 2018, 57, 1646-1654.	0.8	4
132	Feasibility of using optical coherence tomography to detect radiation-induced fibrosis and residual cancer extent after neoadjuvant chemo-radiation therapy: an ex vivo study. Biomedical Optics Express, 2018, 9, 4196.	1.5	4
133	Thromboembolic and bleeding complications in patients with oesophageal cancer. British Journal of Surgery, 2020, 107, 1324-1333.	0.1	4
134	CROSS and beyond: a clinical perspective on the results of the randomized ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study. Chinese Clinical Oncology, 2016, 5, 13.	0.4	4
135	Quantification of the Contribution of Hyperthermia to Results of Cervical Cancer Trials: In Regard to Plataniotis and Dale (Int J Radiat Oncol Biol Phys 2009;73:1538–1544). International Journal of Radiation Oncology Biology Physics, 2009, 75, 634.	0.4	3
136	Definitive chemoradiation for locoregional recurrences of esophageal cancer after primary curative treatment. Ecological Management and Restoration, 2016, 30, 1-5.	0.2	3
137	Neoadjuvant chemotherapy in oesophageal adenocarcinoma. Lancet Oncology, The, 2017, 18, e639.	5.1	3
138	Development of a 70 MHz unit for hyperthermia treatment of deep-seated breast tumors. International Journal of Microwave and Wireless Technologies, 2017, 9, 1317-1324.	1.5	3
139	Lymph node metastases near the celiac trunk should be considered separately from other nodal metastases in patients with cancer of the esophagus or gastroesophageal junction after neoadjuvant treatment and surgery. Journal of Thoracic Disease, 2018, 10, 1511-1521.	0.6	3
140	The effect of air pockets in the urinary bladder on the temperature distribution during loco-regional hyperthermia treatment of bladder cancer patients. International Journal of Hyperthermia, 2018, 35, 441-449.	1.1	3
141	Immediate treatment vs. active-surveillance in very-low-risk prostate cancer: the role of patient-, tumour-, and hospital-related factors. Prostate Cancer and Prostatic Diseases, 2019, 22, 337-343.	2.0	3
142	Management of conjunctival melanoma with local excision and adjuvant brachytherapy. Eye, 2021, 35, 490-498.	1.1	3
143	Prognosis of Interval Distant Metastases After Neoadjuvant Chemoradiotherapy for Esophageal Cancer. Annals of Thoracic Surgery, 2022, 113, 482-490.	0.7	3
144	Evaluation of the antitumor activity of gefitinib (ZD1839) in combination with celecoxib in patients with advanced esophageal cancer. Journal of Clinical Oncology, 2004, 22, 4054-4054.	0.8	3

#	Article	IF	CITATIONS
145	A 70 MHz double waveguide set-up for hyperthermia of deep superficial tumors. , 2016, , .		2
146	Microscopic tumor spread beyond (echo)endoscopically determined tumor borders in esophageal cancer. Radiation Oncology, 2019, 14, 219.	1.2	2
147	A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. Cancers, 2021, 13, 839.	1.7	2
148	Evaluation of the antitumor activity of gefitinib (ZD1839) in combination with celecoxib in patients with advanced esophageal cancer. Journal of Clinical Oncology, 2004, 22, 4054-4054.	0.8	2
149	Development of a 70 MHz unit for hyperthermia treatment of deep seated breast tumors. , 2016, , .		1
150	4D cone-beam CT imaging for guidance in radiation therapy: setup verification by use of implanted fiducial markers. , 2016, , .		1
151	Clinical use of a waveguide hyperthermia system for superficial tumors with deep infiltration. , 2017, ,		1
152	Hyperthermia of deep seated pelvic tumors with a phased array of eight versus four 70 MHz waveguides. , 2017, , .		1
153	Reply to C. Pöttgen et al and YH. Lin et al. Journal of Clinical Oncology, 2021, 39, JCO.21.01980.	0.8	1
154	Treatment decisionâ€making during outpatient clinic visit of patients with esophagogastric cancer. The perspectives of clinicians and patients, a mixed method, multiple case study. Cancer Medicine, 2022, , .	1.3	1
155	Author reply to previously published correspondence. Cancer, 2002, 94, 2316-2317.	2.0	0
156	Regarding Edmunds et al. Cardiac volume effects during chemoradiotherapy for esophageal cancer. Radiotherapy and Oncology, 2015, 114, 130.	0.3	0
157	On the Receiving End of Autonomy and Law. Oncologist, 2017, 22, 1143-1145.	1.9	Ο
158	Chemoradiation in Esophagogastric Junction Cancer. , 2017, , 149-161.		0
159	Tailoring four-dimensional cone-beam CT acquisition settings for fiducial marker-based image guidance in radiation therapy. Journal of Medical Imaging, 2018, 5, 1.	0.8	0
160	Improving survival prediction of oesophageal cancer patients treated with external beam radiotherapy for dysphagia. Acta Oncológica, 2022, 61, 849-855.	0.8	0